GDK PHARMACY: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
GDK PHARMACY
Largest movements
- Stocks and contracts +€43,304
up €43,304 (+18.3%), from €236,104 to €279,407
- Cash +€22,186
up €22,186 (+35.2%), from €63,038 to €85,224
mainly Other debts (+€50,903) and Depreciation (+€13,571)
- Receivables within one year +€18,268
up €18,268 (+8.6%), from €211,616 to €229,883
of which Other amounts receivable: +€11,643
- Deferred charges and accrued income -€8,766
down €8,766 (-66.2%), from €13,233 to €4,467
- Other debts +€50,903
up €50,903 (+49.0%), from €103,935 to €154,838
- Trade debts +€10,525
up €10,525 (+3.7%), from €283,969 to €294,494
- Staff costs +€29,474
up €29,474 (+14.4%), from €204,367 to €233,841
- Gross operating margin +€17,591
up €17,591 (+6.9%), from €256,120 to €273,711
- Depreciation -€9,320
down €9,320 (-40.7%), from €22,891 to €13,571
- Financial charges +€5,610
up €5,610 (+58.1%), from €9,660 to €15,269
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €595,977 | €668,691 | +€72,714 | +12.2% |
| Fixed assets | 21/28 | €71,986 | €69,709 | -€2,278 | -3.2% |
| Tangible fixed assets | 22/27 | €61,289 | €59,011 | -€2,278 | -3.7% |
| Plant, machinery and equipment | 23 | €61,289 | €54,058 | -€7,231 | -11.8% |
| Furniture and vehicles | 24 | - | €4,953 | +€4,953 | |
| Financial fixed assets | 28 | €10,697 | €10,697 | = | 0.0% |
| Current assets | 29/58 | €523,991 | €598,982 | +€74,991 | +14.3% |
| Stocks and contracts in progress | 3 | €236,104 | €279,407 | +€43,304 | +18.3% |
| Stocks | 30/36 | €236,104 | €279,407 | +€43,304 | +18.3% |
| Amounts receivable within one year | 40/41 | €211,616 | €229,883 | +€18,268 | +8.6% |
| Trade receivables | 40 | €205,117 | €211,742 | +€6,625 | +3.2% |
| Other amounts receivable | 41 | €6,499 | €18,142 | +€11,643 | +179% |
| Cash at bank and in hand | 54/58 | €63,038 | €85,224 | +€22,186 | +35.2% |
| Deferred charges and accrued income | 490/1 | €13,233 | €4,467 | -€8,766 | -66.2% |
| Total equity and liabilities | 10/49 | €595,977 | €668,691 | +€72,714 | +12.2% |
| Equity | 10/15 | €180,561 | €191,125 | +€10,563 | +5.9% |
| Contributions | 10/11 | €12,403 | €18,600 | +€6,197 | +50.0% |
| Reserves | 13 | €1,859 | €1,859 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,859 | €1,859 | = | 0.0% |
| Reserves not available under the articles | 1311 | €1,859 | €1,859 | = | 0.0% |
| Profit (loss) carried forward | 14 | €166,299 | €170,666 | +€4,366 | +2.6% |
| Amounts payable | 17/49 | €415,416 | €477,566 | +€62,150 | +15.0% |
| Amounts payable within one year | 42/48 | €415,416 | €477,566 | +€62,150 | +15.0% |
| Trade debts | 44 | €283,969 | €294,494 | +€10,525 | +3.7% |
| Suppliers | 440/4 | €283,969 | €294,494 | +€10,525 | +3.7% |
| Taxes, remuneration and social security | 45 | €27,512 | €28,234 | +€722 | +2.6% |
| Taxes | 450/3 | €8,920 | €6,351 | -€2,569 | -28.8% |
| Remuneration and social security | 454/9 | €18,592 | €21,883 | +€3,291 | +17.7% |
| Other amounts payable | 47/48 | €103,935 | €154,838 | +€50,903 | +49.0% |
| Remuneration, social security and pensions | 62 | €204,367 | €233,841 | +€29,474 | +14.4% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €22,891 | €13,571 | -€9,320 | -40.7% |
| Other operating charges | 640/8 | €622 | €669 | +€47 | +7.5% |
| Gross operating margin | 9900 | €256,120 | €273,711 | +€17,591 | +6.9% |
| Operating profit (loss) | 9901 | €28,240 | €25,630 | -€2,610 | -9.2% |
| Financial income | 75/76B | €2,341 | €346 | -€1,995 | -85.2% |
| Recurring financial income | 75 | €2,341 | €346 | -€1,995 | -85.2% |
| Financial charges | 65/66B | €9,660 | €15,269 | +€5,610 | +58.1% |
| Recurring financial charges | 65 | €9,660 | €15,269 | +€5,610 | +58.1% |
| Profit (loss) for the period before taxes | 9903 | €20,922 | €10,707 | -€10,215 | -48.8% |
| Income taxes | 67/77 | €8,920 | €6,341 | -€2,579 | -28.9% |
| Profit (loss) for the period | 9904 | €12,002 | €4,366 | -€7,636 | -63.6% |
| Profit (loss) for the period to be appropriated | 9905 | €12,002 | €4,366 | -€7,636 | -63.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 22 October 2026 via checked.be.